Metformin: Restraining Nucleocytoplasmic Shuttling to Fight Cancer and Aging

Jorge Iván Castillo-Quan; T Keith Blackwell

doi:10.1016/j.cell.2016.11.058

Metformin: Restraining Nucleocytoplasmic Shuttling to Fight Cancer and Aging

Cell. 2016 Dec 15;167(7):1670-1671. doi: 10.1016/j.cell.2016.11.058.

Authors

Jorge Iván Castillo-Quan¹, T Keith Blackwell²

Affiliations

¹ Research Division, Joslin Diabetes Center, Boston, MA 02215, USA; Department of Genetics and Harvard Stem Cell Institute, Harvard Medical School, Boston MA 02115, USA.
² Research Division, Joslin Diabetes Center, Boston, MA 02215, USA; Department of Genetics and Harvard Stem Cell Institute, Harvard Medical School, Boston MA 02115, USA. Electronic address: keith.blackwell@joslin.harvard.edu.

PMID: 27984715
DOI: 10.1016/j.cell.2016.11.058

Abstract

In this issue of Cell, Wu et al. employed C. elegans and human cell experiments to identify a pathway through which metformin increases lifespan and inhibits growth. A key transcriptional target, ACAD10, is activated when metformin induces nuclear exclusion of the GTPase RagC, thereby inhibiting mTORC1 through an unexpected mechanism.

Publication types

Comment

MeSH terms

Active Transport, Cell Nucleus
Aging / drug effects
Animals
Caenorhabditis elegans / drug effects*
Humans
Metformin / pharmacology*
Neoplasms / drug therapy

Substances

Metformin

Abstract

Publication types

MeSH terms

Substances

Grants and funding